{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fote G"],"funding":["NIA NIH HHS","NCRR NIH HHS"],"pagination":["1161-1171"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9788856"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["83(3)"],"pubmed_abstract":["<h4>Background</h4>Altered plasma levels of sphingolipids, including sphingomyelins (SM), have been found in mouse models of Alzheimer's disease (AD) and in AD patient plasma samples.<h4>Objective</h4>This study assesses fourteen plasma SM species in a late-onset AD (LOAD) patient cohort (n = 138).<h4>Methods</h4>Specimens from control, preclinical, and symptomatic subjects were analyzed using targeted mass-spectrometry-based metabolomic methods.<h4>Results</h4>Total plasma SM levels were not significantly affected by age or cognitive status. However, one metabolite that has been elevated in manifest AD in several recent studies, SM OHC14:1, was reduced significantly in pre-clinical AD and MCI relative to normal controls.<h4>Conclusion</h4>We recommend additional comprehensive plasma lipid"],"journal":["Journal of Alzheimer's disease : JAD"],"pubmed_title":["Plasma Sphingomyelins in Late-Onset Alzheimer's Disease."],"pmcid":["PMC9788856"],"funding_grant_id":["F30 AG060704","R01 AG030753","M01 RR000865","K08 AG022228","P50 AG005142","UL1 RR033176","U19 AG032438","P50 AG016570"],"pubmed_authors":["Wu J","Mapstone M","Macciardi F","Fote G","Federoff HJ","Fiandaca MS"],"additional_accession":[]},"is_claimable":false,"name":"Plasma Sphingomyelins in Late-Onset Alzheimer's Disease.","description":"<h4>Background</h4>Altered plasma levels of sphingolipids, including sphingomyelins (SM), have been found in mouse models of Alzheimer's disease (AD) and in AD patient plasma samples.<h4>Objective</h4>This study assesses fourteen plasma SM species in a late-onset AD (LOAD) patient cohort (n = 138).<h4>Methods</h4>Specimens from control, preclinical, and symptomatic subjects were analyzed using targeted mass-spectrometry-based metabolomic methods.<h4>Results</h4>Total plasma SM levels were not significantly affected by age or cognitive status. However, one metabolite that has been elevated in manifest AD in several recent studies, SM OHC14:1, was reduced significantly in pre-clinical AD and MCI relative to normal controls.<h4>Conclusion</h4>We recommend additional comprehensive plasma lipid","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2025-04-18T17:15:05.444Z","creation":"2025-04-07T04:48:38.44Z"},"accession":"S-EPMC9788856","cross_references":{"pubmed":["34397408"],"doi":["10.3233/jad-200871","10.3233/JAD-200871"]}}